Study on the relationship of cPLA2, CK-MB, and membrane phospholipid content in acute myocardial infarction.
Increased plasma creatine kinase-myoglobin (CK-MB) occurs in patients with acute myocardial infarction (AMI), but its underlying relationship with cytosolic phospholipase A2 (cPLA2) is poorly understood. In the present study we sought to determine cPLA2 activation and its relationship with plasma and myocardial CK-MB level and membrane phospholipids (PLs) in an animal model of AMI. AMI was induced in 60 male Sprague-Dawley rats by ligating the left anterior descending of coronary artery. Rats were randomized into six groups at 0 (sham group), 1, 2, 4, 6, and 12 h after AMI onset (ten rats in each group). cPLA2 was detected by reverse transcription polymerase chain reaction and immunohistochemical staining for mRNA and protein expression, respectively. Plasma and myocardial CK-MB activity were measured by inhibition kinetics, and membrane PLs were determined by phosphorus quantitative method. Myocardial cPLA2 expression increased from 1 h and reached a peak at 2 h after AMI onset (p < 0.01) followed by a decrease but still remained high, whereas plasma CK-MB significantly increased in rats from 4 h after the onset of AMI (p < 0.05). During the first 6 h of AMI, a negative correlation existed between myocardial cPLA2 and membrane PLs (r = -0.504, p < 0.01), whereas myocardial cPLA2 levels were positively associated with plasma CK-MB (r = 0.741, p < 0.01) but negatively correlated with myocardial CK-MB in AMI groups (r = -0.785, p < 0.01). Myocardial cPLA2 level increased and is positively correlated with plasma CK-MB activity and negatively correlated with membrane phospholipid content in AMI rats at early stage.
Wei-hua
Li
L
Department of Cardiology, The First Affiliated Hospital of Xiamen University, 10 Shanggu Street, Zhenhai Road, Xiamen, 361003, People's Republic of China. liweihuaxm@hotmail.com
Jun-yu
Han
H
Chang-qing
Sun
S
Yong-jun
Guo
G
Qiang
Xie
X
Kai-min
Lin
L
Rong
Wu
W
Yan
Zhao
Z
Lin
Lin
L
D000818:Animals; D052279:Creatine Kinase, MB Form / Q000097:blood / Q000378:metabolism*; D004195:Disease Models, Animal; D015971:Gene Expression Regulation, Enzymologic; D054513:Group IV Phospholipases A2 / Q000235:genetics / Q000378:metabolism*; D007150:Immunohistochemistry; D008297:Male; D008563:Membrane Lipids / Q000378:metabolism*; D009203:Myocardial Infarction / Q000201:enzymology* / Q000235:genetics; D009206:Myocardium / Q000201:enzymology*; D010743:Phospholipids / Q000378:metabolism*; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013997:Time Factors
D008563:Membrane Lipids; D010743:Phospholipids; D012333:RNA, Messenger; D052279:Creatine Kinase, MB Form; D054513:Group IV Phospholipases A2; C516391:Pla2g4a protein, rat